ORIC Pharmaceuticals Q3 net loss widens as R&D expenses rise
ORIC•ORIC Pharmaceuticals reported a third-quarter net loss of $48.1 million as operating expenses rose to $51.6 million, mainly due to higher research and development spending on rinzimetostat. It ended the quarter with $345 million in cash and investments, which it expects to fund operations into the second half of 2028 and beyond.
1. Quarterly results
ORIC Pharmaceuticals reported a third-quarter net loss of $48.08 million and operating expenses of $51.55 million. Higher external costs to advance rinzimetostat drove the increase in research and development expenses; lower enozertinib costs partly offset the rise.
2. Trials and cash outlook
The company said its $345 million in cash and investments is expected to fund operations into the second half of 2028 and beyond. ORIC has initiated the Himalayas-1 Phase 3 trial of rinzimetostat in metastatic castration-resistant prostate cancer and expects to initiate the Redwood-1 Phase 3 trial of enozertinib in the first half of 2027.



